FIELD: medicine.
SUBSTANCE: present invention relates to a method of treating allergic diseases by administering a therapeutically effective amount of a benzo[b]azepine TLR8 receptor agonist VTX-378 - (1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide or a pharmaceutically acceptable salt thereof. Said benzo[b]azepine VTX-378 is administered intranasally in a dosage form containing a single dose of 25 mcg to 1,000 mcg. Administration is daily, three times a week (intermittently), twice a week, once a week, every 14 days, once a month or once every 6-8 weeks.
EFFECT: treatment with benzo[b]azepine VTX-378 significantly reduced allergic reaction in an experimental model of allergic rhinitis, sensitised with ragweed pollen allergen, and showed an increase in volume of nasal cavity.
19 cl, 14 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
| IMMUNOSTIMULATING G,U-CONTAINING OLYGORIBONUCLEOTIDES | 2003 |
|
RU2302865C2 |
| ALLERGIC SENSITISATION PREVENTION | 2008 |
|
RU2429881C2 |
| IMPROVED IMMUNOLOGICAL COMPOSITION | 2012 |
|
RU2664730C2 |
| ALLERGEN-CONTAINING DOSAGE FORM | 2003 |
|
RU2372074C2 |
| IMMUNOREGULATORY VACCINE | 2013 |
|
RU2650709C2 |
| METHODS FOR THE TREATMENT OF ALLERGY AND INCREASING THE EFFICIENCY OF ALLERGEN-SPECIFIC IMMUNOTHERAPY BY INTRODUCING IL-4R INHIBITOR | 2014 |
|
RU2789047C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS T-CELL LYMPHOMA | 2014 |
|
RU2669941C2 |
| METHOD FOR ALLERGIC BRONCHIAL ASTHMA TREATMENT, BASED ON CYTOKINES IL-4 AND IL-13 GENES EXPRESSION INHIBITION USING SIRNA MOLECULES | 2016 |
|
RU2615463C1 |
